AR008198A1 - Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona - Google Patents

Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona

Info

Publication number
AR008198A1
AR008198A1 ARP980102649A ARP980102649A AR008198A1 AR 008198 A1 AR008198 A1 AR 008198A1 AR P980102649 A ARP980102649 A AR P980102649A AR P980102649 A ARP980102649 A AR P980102649A AR 008198 A1 AR008198 A1 AR 008198A1
Authority
AR
Argentina
Prior art keywords
thiazolin
amino
methyl
preparing
pharmaceutical composition
Prior art date
Application number
ARP980102649A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of AR008198A1 publication Critical patent/AR008198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Un procedimiento para preparar una composición farmacéutica que comprende de 2 a 12 mg de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona [Compuesto (I)] en una forma farmacéuticamente aceptable y un vehículo para elmismo farmacéuticamente aceptable, que comprende mezclar2 a 12 mg de Compuesto (I) en una forma farmacéuticamente aceptable y opcionalmente, después de ello, formular la composición producida en una formaadministrable. El compuesto (I) proporciona un efecto especialmente beneficioso sobre el control glicémico y, por lo tanto, es particularmente útil para eltratamiento de la diabetes mellitus, especialmente la diabetes de tipo II, y los trastornos asociados con la diabetes mellitus.
ARP980102649A 1997-06-05 1998-06-04 Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona AR008198A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
AR008198A1 true AR008198A1 (es) 1999-12-29

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102649A AR008198A1 (es) 1997-06-05 1998-06-04 Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
ARP980102650A AR015120A1 (es) 1997-06-05 1998-06-04 Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP980102650A AR015120A1 (es) 1997-06-05 1998-06-04 Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1112926C (es)
AP (1) AP1214A (es)
AR (2) AR008198A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2333352A1 (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR200002790T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA984826B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PL351684A1 (en) * 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
WO2000064892A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
CA2260044A1 (en) * 1996-07-12 1998-01-22 Stephen Alistair Smith Novel treatment of leptine resistance

Also Published As

Publication number Publication date
EA002384B1 (ru) 2002-04-25
EA199901116A1 (ru) 2000-06-26
JP2001521553A (ja) 2001-11-06
CN1259050A (zh) 2000-07-05
AP9901696A0 (en) 1999-12-31
PE78899A1 (es) 1999-10-22
CN1112926C (zh) 2003-07-02
ZA984826B (en) 1999-08-03
TW570797B (en) 2004-01-11
NZ513922A (en) 2001-09-28
TR199902963T2 (xx) 2000-02-21
CO4940400A1 (es) 2000-07-24
ZA9811572B (en) 1999-07-22
SK164899A3 (en) 2000-11-07
BG104048A (bg) 2000-07-31
CA2333352A1 (en) 1998-12-10
NZ523725A (en) 2004-09-24
HUP0004070A3 (en) 2002-03-28
NO995938D0 (no) 1999-12-03
NO20040738L (no) 2000-02-02
AR015120A1 (es) 2001-04-18
HUP0004070A2 (hu) 2002-02-28
NO995938L (no) 2000-02-02
TR200002790T2 (tr) 2001-11-21
CA2292629A1 (en) 1998-12-10
CN1430959A (zh) 2003-07-23
CA2292629C (en) 2004-01-06
BR9810405A (pt) 2000-08-29
ID24264A (id) 2000-07-13
OA11306A (en) 2003-10-22
UY25032A1 (es) 1998-11-26
IL133074A0 (en) 2001-03-19
MXPA99011322A (es) 2004-12-02
AU8215098A (en) 1998-12-21
AP1214A (en) 2003-10-08
DZ2510A1 (fr) 2003-01-25
PL337201A1 (en) 2000-08-14
CN1526391A (zh) 2004-09-08
KR20010013410A (ko) 2001-02-26
EP0998284A1 (en) 2000-05-10
WO1998055122A1 (en) 1998-12-10
GB9711683D0 (en) 1997-08-06

Similar Documents

Publication Publication Date Title
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
UY25049A1 (es) Composiciones para tratamiento para diabetes mellitus
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
AR008198A1 (es) Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
CO4940454A1 (es) Nuevo metodo de tratamiento
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
UY25102A1 (es) Nueva composición para el tratamiento de diabetes mellitus
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
BR0111536A (pt) Sal de tiazolidinediona para tratamento de diabetes mellitus
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
NZ510672A (en) Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione
EA200300004A1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
ECSP003434A (es) Nuevos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal